French Trial Tragedy: Janssen Halts FAAH Inhibitor Trial
This article was originally published in Scrip
Janssen has voluntarily suspended dosing in two Phase II studies of its experimental FAAH inhibitor JNJ-42165279; the drug is in the same class as the compound at the heart of the clinical trial tragedy in France.
You may also be interested in...
Bial-Portela's drug had 'unique toxicity' not found with other compounds in the class, FDA says; findings could allow studies of Janssen's and Pfizer's investigational FAAH inhibitors that have been on hold to proceed.
This quarter has already seen a complete response letter for Iterum Therapeutics’ antibiotic sulopenem but a raft of other products are expecting approval decisions from the US Food and Drug Administration in the next three months. With the help of analysts at Biomedtracker, Scrip takes a look at 10 of the more interesting ones.
Sanofi is beefing up its investment in mRNA vaccine technology with a €400m annual injection into a dedicated mRNA Center of Excellence as it seeks to be at the forefront of the next generation of candidates.